Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocol.

Morrow A, Hogden E, Kang YJ, Steinberg J, Canfell K, Solomon MJ, Kench JG, Gill AJ, Shaw T, Pachter N, Parkinson B, Wolfenden L, Mitchell G, Macrae F, Tucker K, Taylor N.

Trials. 2019 Jun 20;20(1):373. doi: 10.1186/s13063-019-3457-6.

2.

Towards the global elimination of cervical cancer.

Canfell K.

Papillomavirus Res. 2019 Jun 6:100170. doi: 10.1016/j.pvr.2019.100170. [Epub ahead of print]

3.

The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study.

Laaksonen MA, MacInnis RJ, Canfell K, Giles GG, Hull P, Shaw JE, Cumming RG, Gill TK, Banks E, Mitchell P, Byles JE, Magliano DJ, Hirani V, Connah D, Vajdic CM.

Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32420. [Epub ahead of print]

PMID:
31107541
4.

Correction: Anal cancer in high-income countries: Increasing burden of disease.

Kang YJ, Smith M, Canfell K.

PLoS One. 2019 May 8;14(5):e0216884. doi: 10.1371/journal.pone.0216884. eCollection 2019.

5.

Towards global elimination of cervical cancer in all groups of women - Authors' reply.

Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, Castle PE, Bray F, Canfell K.

Lancet Oncol. 2019 May;20(5):e239. doi: 10.1016/S1470-2045(19)30236-0. No abstract available.

PMID:
31044714
6.

Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions.

Velentzis LS, Brotherton JML, Canfell K.

Climacteric. 2019 Apr 29:1-7. doi: 10.1080/13697137.2019.1600500. [Epub ahead of print]

PMID:
31030590
7.

The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.

Laaksonen MA, Arriaga ME, Canfell K, MacInnis RJ, Byles JE, Banks E, Shaw JE, Mitchell P, Giles GG, Magliano DJ, Gill TK, Klaes E, Velentzis LS, Hirani V, Cumming RG, Vajdic CM.

Gynecol Oncol. 2019 Jun;153(3):580-588. doi: 10.1016/j.ygyno.2019.03.102. Epub 2019 Mar 29.

PMID:
30935715
8.

Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?

Luo Q, Steinberg J, O'Connell DL, Yu XQ, Caruana M, Wade S, Pesola F, Grogan PB, Dessaix A, Freeman B, Dunlop S, Sasieni P, Blakely T, Banks E, Canfell K.

Lung Cancer. 2019 Apr;130:208-215. doi: 10.1016/j.lungcan.2019.02.028. Epub 2019 Feb 28.

9.

The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.

Hall MT, Smith MA, Lew JB, O'Hallahan J, Fentiman G, Neal H, Sage M, Canfell K.

Gynecol Oncol. 2019 Mar;152(3):472-479. doi: 10.1016/j.ygyno.2018.10.045.

PMID:
30876491
10.

Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

Velentzis LS, Smith MA, Simms KT, Lew JB, Hall M, Hughes S, Yuill S, Killen J, Keane A, Butler K, Darlington-Brown J, Hui H, Brotherton JML, Skinner R, Brand A, Roeske L, Heley S, Carter J, Bateson D, Frazer I, Garland SM, Guy R, Hammond I, Grogan P, Arbyn M, Castle PE, Saville M, Armstrong BK, Canfell K.

Gynecol Oncol. 2019 Mar;152(3):465-471. doi: 10.1016/j.ygyno.2018.12.019.

PMID:
30876490
11.

The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study.

Arriaga ME, Vajdic CM, Canfell K, MacInnis RJ, Banks E, Byles JE, Magliano DJ, Taylor AW, Mitchell P, Giles GG, Shaw JE, Gill TK, Klaes E, Velentzis LS, Cumming RG, Hirani V, Laaksonen MA.

Int J Cancer. 2019 Feb 25. doi: 10.1002/ijc.32231. [Epub ahead of print]

PMID:
30802946
12.

Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.

Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, Castle PE, Bray F, Canfell K.

Lancet Oncol. 2019 Mar;20(3):394-407. doi: 10.1016/S1470-2045(18)30836-2. Epub 2019 Feb 19.

PMID:
30795950
13.

A Prospective Study of Health Conditions Related to Alcohol Consumption Cessation Among 97,852 Drinkers Aged 45 and Over in Australia.

Sarich P, Canfell K, Banks E, Paige E, Egger S, Joshy G, Korda R, Weber M.

Alcohol Clin Exp Res. 2019 Apr;43(4):710-721. doi: 10.1111/acer.13981. Epub 2019 Mar 7.

PMID:
30758044
14.

Cancer elimination thresholds: one size does not fit all - Authors' reply.

Hall MT, Smith MA, Brotherton JML, Simms KT, Canfell K.

Lancet Public Health. 2019 Feb;4(2):e87. doi: 10.1016/S2468-2667(18)30258-5. No abstract available.

15.

The burden of cervical cancer in Vietnam: Synthesis of the evidence.

Thi Nguyen DN, Simms K, Vu Nguyen HQ, Van Tran T, Nguyen NH, LaMontagne DS, Castle P, Canfell K.

Cancer Epidemiol. 2019 Apr;59:83-103. doi: 10.1016/j.canep.2018.11.008. Epub 2019 Jan 30. Review.

PMID:
30710841
16.

Association of ten gastrointestinal and other medical conditions with positivity to faecal occult blood testing in routine screening: a large prospective study of women in England.

He E, Alison R, Blanks R, Pirie K, Reeves G, Ward RL, Steele R, Patnick J, Canfell K, Beral V, Green J.

Int J Epidemiol. 2019 Jan 21. doi: 10.1093/ije/dyy271. [Epub ahead of print]

17.

The burden of pancreatic cancer in Australia attributable to smoking.

Arriaga ME, Vajdic CM, MacInnis RJ, Canfell K, Magliano DJ, Shaw JE, Byles JE, Giles GG, Taylor AW, Gill TK, Hirani V, Cumming RG, Mitchell RP, Banks E, Marker J, Adelstein BA, Laaksonen MA.

Med J Aust. 2019 Mar;210(5):213-220. doi: 10.5694/mja2.12108. Epub 2019 Jan 18.

PMID:
30656698
18.

Trends in Colon and Rectal Cancer Incidence in Australia from 1982 to 2014: Analysis of Data on Over 375,000 Cases.

Feletto E, Yu XQ, Lew JB, St John DJB, Jenkins MA, Macrae FA, Mahady SE, Canfell K.

Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):83-90. doi: 10.1158/1055-9965.EPI-18-0523. Epub 2018 Dec 7.

PMID:
30530848
19.

Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.

Saville M, Sultana F, Malloy MJ, Velentzis LS, Caruana M, Ip ELO, Keung MHT, Canfell K, Brotherton JML, Hawkes D.

J Clin Microbiol. 2019 Jan 30;57(2). pii: e01239-18. doi: 10.1128/JCM.01239-18. Print 2019 Feb.

20.

A hepatitis B vaccine booster shot at age 10 could be cost-saving in China: But is it too soon to tell?

Simms KT, Smith MA, Caruana M, Canfell K.

Int J Infect Dis. 2019 Jan;78:128-129. doi: 10.1016/j.ijid.2018.11.007. Epub 2018 Nov 15. No abstract available.

21.

Lung cancer mortality in Australia: Projected outcomes to 2040.

Luo Q, Yu XQ, Wade S, Caruana M, Pesola F, Canfell K, O'Connell DL.

Lung Cancer. 2018 Nov;125:68-76. doi: 10.1016/j.lungcan.2018.09.001. Epub 2018 Sep 8.

22.

Aboriginal women have a higher risk of cervical abnormalities at screening; South Australia, 1993-2016.

Li M, Roder D, Whop LJ, Diaz A, Baade PD, Brotherton JM, Canfell K, Cunningham J, Garvey G, Moore SP, O'Connell DL, Valery PC, Condon JR.

J Med Screen. 2019 Jun;26(2):104-112. doi: 10.1177/0969141318810719. Epub 2018 Nov 12.

PMID:
30419778
23.

Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.

Salagame U, Banks E, O'Connell DL, Egger S, Canfell K.

PLoS One. 2018 Nov 7;13(11):e0205034. doi: 10.1371/journal.pone.0205034. eCollection 2018.

24.

Anal cancer in high-income countries: Increasing burden of disease.

Kang YJ, Smith M, Canfell K.

PLoS One. 2018 Oct 19;13(10):e0205105. doi: 10.1371/journal.pone.0205105. eCollection 2018. Erratum in: PLoS One. 2019 May 8;14(5):e0216884.

25.

The projected timeframe until cervical cancer elimination in Australia: a modelling study.

Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K.

Lancet Public Health. 2019 Jan;4(1):e19-e27. doi: 10.1016/S2468-2667(18)30183-X. Epub 2018 Oct 2.

26.

Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand.

Smith MA, Hall M, Lew JB, Canfell K.

Vaccine. 2018 Oct 8;36(42):6314-6324. doi: 10.1016/j.vaccine.2018.08.063. Epub 2018 Sep 14.

PMID:
30224201
27.

Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.

Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Greuter MJE, Coupé VMH, Canfell K.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1450-1461. doi: 10.1158/1055-9965.EPI-18-0128. Epub 2018 Sep 6.

PMID:
30190276
28.

Health services costs for cancer care in Australia: Estimates from the 45 and Up Study.

Goldsbury DE, Yap S, Weber MF, Veerman L, Rankin N, Banks E, Canfell K, O'Connell DL.

PLoS One. 2018 Jul 30;13(7):e0201552. doi: 10.1371/journal.pone.0201552. eCollection 2018.

29.

Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study.

Yap S, Goldsbury D, Yap ML, Yuill S, Rankin N, Weber M, Canfell K, O'Connell DL.

Lung Cancer. 2018 Aug;122:171-179. doi: 10.1016/j.lungcan.2018.06.006. Epub 2018 Jun 9.

PMID:
30032827
30.

The future burden of lung cancer attributable to current modifiable behaviours: a pooled study of seven Australian cohorts.

Laaksonen MA, Canfell K, MacInnis R, Arriaga ME, Banks E, Magliano DJ, Giles GG, Cumming RG, Byles JE, Mitchell P, Gill TK, Hirani V, McCullough S, Shaw JE, Taylor AW, Adelstein BA, Vajdic CM.

Int J Epidemiol. 2018 Dec 1;47(6):1772-1783. doi: 10.1093/ije/dyy136.

PMID:
29982519
31.

Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30-44 years: A case-control study in New South Wales, Australia.

Xu H, Egger S, Velentzis LS, O'Connell DL, Banks E, Darlington-Brown J, Canfell K, Sitas F.

Cancer Epidemiol. 2018 Aug;55:162-169. doi: 10.1016/j.canep.2018.05.013. Epub 2018 Jul 3.

PMID:
29980028
32.

Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention.

Jamieson L, Garvey G, Hedges J, Mitchell A, Dunbar T, Leane C, Hill I, Warren K, Brown A, Ju X, Roder D, Logan R, Johnson N, Smith M, Antonsson A, Canfell K.

JMIR Res Protoc. 2018 Jun 8;7(6):e10503. doi: 10.2196/10503.

33.

Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012).

Diaz A, Baade PD, Valery PC, Whop LJ, Moore SP, Cunningham J, Garvey G, Brotherton JML, O'Connell DL, Canfell K, Sarfati D, Roder D, Buckley E, Condon JR.

PLoS One. 2018 May 8;13(5):e0196764. doi: 10.1371/journal.pone.0196764. eCollection 2018.

34.

Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.

Wade S, Weber M, Caruana M, Kang YJ, Marshall H, Manser R, Vinod S, Rankin N, Fong K, Canfell K.

J Thorac Oncol. 2018 Aug;13(8):1094-1105. doi: 10.1016/j.jtho.2018.04.006. Epub 2018 Apr 22.

PMID:
29689434
35.

Cervical screening in HPV-vaccinated populations.

Canfell K.

Climacteric. 2018 Jun;21(3):227-234. doi: 10.1080/13697137.2018.1428296. Epub 2018 Mar 22. Review.

PMID:
29565690
36.

Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.

Nair-Shalliker V, Bang A, Weber M, Goldsbury DE, Caruana M, Emery J, Banks E, Canfell K, O'Connell DL, Smith DP.

Sci Rep. 2018 Mar 9;8(1):4261. doi: 10.1038/s41598-018-22589-y.

37.

Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.

Hall MT, Simms KT, Lew JB, Smith MA, Saville M, Canfell K.

PLoS One. 2018 Feb 14;13(2):e0185332. doi: 10.1371/journal.pone.0185332. eCollection 2018.

38.

Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.

Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Sarfati D, Greuter MJE, Coupé VMH, Canfell K.

Int J Cancer. 2018 Jul 15;143(2):269-282. doi: 10.1002/ijc.31314. Epub 2018 Mar 8.

PMID:
29441568
39.

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.

BMJ Open. 2018 Jan 26;8(1):e016700. doi: 10.1136/bmjopen-2017-016700. Erratum in: BMJ Open. 2018 Mar 8;8(3):e016700corr1.

40.

Inaccurate and fundamentally flawed analysis risks undermining confidence in cervical screening programs.

Smith MA, Brotherton JML, Hammond IG, Anderson L, Simms KT, Saville M, Canfell K.

J Am Soc Cytopathol. 2018 Nov - Dec;7(6):336-338. doi: 10.1016/j.jasc.2018.08.002. Epub 2018 Oct 3. No abstract available.

PMID:
31043305
41.

Cost-effectiveness estimates: the need for complete reporting - Authors' reply.

Lew JB, Simms KT, Smith MA, Saville M, Hammond I, Canfell K.

Lancet Public Health. 2017 May;2(5):e212. doi: 10.1016/S2468-2667(17)30076-2. Epub 2017 Apr 28. No abstract available.

42.

Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.

Lew JB, St John DJB, Xu XM, Greuter MJE, Caruana M, Cenin DR, He E, Saville M, Grogan P, Coupé VMH, Canfell K.

Lancet Public Health. 2017 Jul;2(7):e331-e340. doi: 10.1016/S2468-2667(17)30105-6. Epub 2017 Jun 26.

43.

Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.

Simms KT, Laprise JF, Smith MA, Lew JB, Caruana M, Brisson M, Canfell K.

Lancet Public Health. 2016 Dec;1(2):e66-e75. doi: 10.1016/S2468-2667(16)30019-6. Epub 2016 Nov 29.

44.

Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.

Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, Caruana M, Velentzis LS, Bessell T, Saville M, Hammond I, Canfell K.

Lancet Public Health. 2017 Feb;2(2):e96-e107. doi: 10.1016/S2468-2667(17)30007-5. Epub 2017 Feb 7.

45.

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.

Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C.

Lancet Public Health. 2016 Nov;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9. Epub 2016 Sep 27. Review.

46.

Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort.

He E, Lew JB, Egger S, Banks E, Ward RL, Beral V, Canfell K.

Prev Med. 2018 Jan;106:185-193. doi: 10.1016/j.ypmed.2017.10.032. Epub 2017 Nov 3.

PMID:
29109015
47.

Impact of the National Cervical Screening Programme in New Zealand by age: analysis of cervical cancer trends 1985-2013 in all women and in Māori women.

Smith MA, Edwards S, Canfell K.

Cancer Causes Control. 2017 Dec;28(12):1393-1404. doi: 10.1007/s10552-017-0967-y. Epub 2017 Oct 6.

PMID:
28986722
48.

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.

PLoS Med. 2017 Sep 19;14(9):e1002388. doi: 10.1371/journal.pmed.1002388. eCollection 2017 Sep.

49.

How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.

Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, Canfell K.

Int J Cancer. 2017 Dec 15;141(12):2410-2422. doi: 10.1002/ijc.30926. Epub 2017 Oct 5.

50.

A new era for cervical screening in Australia: Watch this space!

Hammond I, Canfell K, Saville M.

Aust N Z J Obstet Gynaecol. 2017 Oct;57(5):499-501. doi: 10.1111/ajo.12669. Epub 2017 Aug 2. No abstract available.

PMID:
28766704

Supplemental Content

Loading ...
Support Center